Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals 8/14/2025 Earnings Report

Telomir Pharmaceuticals logo
$1.57 -0.03 (-1.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.54 -0.03 (-1.85%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Tuesday
Telomir Flat on Trial Data Release
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
TELO Announces Another Important Breakthrough
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

View Telomir Pharmaceuticals Profile

More Earnings Resources from MarketBeat